Switzerland’s Federal Office of Public Health recommended Novavax Nuvaxovid COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that Switzerland’s Federal Office of Public Health had recommended Nuvaxovid (NVX-CoV2373) as…
On Oct. 10, 2022, Novavax announced that Switzerland’s Federal Office of Public Health had recommended Nuvaxovid (NVX-CoV2373) as…
On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were…
On Sept. 16, 2022, Novavax announced that the Taiwan Food and Drug Administration had granted expanded emergency use…
On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use…
On Sept. 13, 2022, Novavax and Serum Institute of India, the world’s largest vaccine manufacturer by volume, announced…
On Sept. 2, 2022, Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, had expanded its temporary…
On Sept. 2, 2022, Novavax announced that the World Health Organization (WHO) had approved a variation to allow…
On Sept. 1, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional marketing…
On Aug. 26, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Aug. 19, 2022, Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received expanded emergency use…
On Aug. 18, 2022, Novavax announced that New Zealand’s Medsafe had granted expanded provisional approval for Nuvaxovid (NVX-CoV2373)…
On Aug. 12, 2022, Novavax announced that partner, SK bioscience, had received a Post Approval Change Application approval…
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…
On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of…
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
On Feb. 14, 2022, Novavax announced that the Singapore Health Sciences Authority (HSA) had issued interim authorization for…
On Feb. 14, 2022, Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional…
On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
On Jan. 10, 2022, in a first-of-its-kind surgery, a 57-year-old patient with terminal heart disease received a successful…